ロード中...
A Phase I/II Open‐Label Study of Nivolumab in Previously Treated Advanced or Recurrent Nasopharyngeal Carcinoma and Other Solid Tumors
LESSONS LEARNED. Nivolumab treatment at doses of 3 mg/kg once every 2 weeks (Q2W), 240 mg Q2W, and 360 mg once every 3 weeks was well tolerated in the Chinese population, with no new safety signals identified. Comparison of intensive pharmacokinetic profiles of nivolumab at 3 mg/kg Q2W in Chinese ve...
保存先:
| 出版年: | Oncologist |
|---|---|
| 主要な著者: | , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley & Sons, Inc.
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6656473/ https://ncbi.nlm.nih.gov/pubmed/31048330 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0284 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|